news_6

BeiGene Announces First Presentation of the Phase 3 ALPINE Trial Comparing BRUKINSA® (Zanubrutinib) to Ibrutinib in Chronic Lymphocytic Leukemia to Be Featured in Presidential Symposium at EHA2021

BRUKINSA demonstrated superior objective response rate by investigator assessment in the planned interim analysis BRUKINSA was associated with a statistically...